77 related articles for article (PubMed ID: 10195233)
1. Post-HAART therapy research.
Gallo RC
J Hum Virol; 1998; 1(2):67-8. PubMed ID: 10195233
[No Abstract] [Full Text] [Related]
2. Biological treatment approaches, including Tat toxoid vaccine: interview with Robert Gallo, M.D. Interview by John S. James.
Gallo R
AIDS Treat News; 1999 Sep; (No 327):1-5. PubMed ID: 11366583
[TBL] [Abstract][Full Text] [Related]
3. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
[No Abstract] [Full Text] [Related]
4. New concepts for future control of HIV derived from studies of pathogenesis.
Gallo RC
Int J Antimicrob Agents; 2000 Dec; 16(4):421-3. PubMed ID: 11118851
[No Abstract] [Full Text] [Related]
5. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
Fischer M; Joos B; Hirschel B; Bleiber G; Weber R; Günthard HF;
J Infect Dis; 2004 Dec; 190(11):1979-88. PubMed ID: 15529263
[TBL] [Abstract][Full Text] [Related]
6. It's the immune system, stupid.
STEP Perspect; 1999; 99(1):5. PubMed ID: 11367162
[TBL] [Abstract][Full Text] [Related]
7. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea: what it is. New Mexico AIDS InfoNet.
Newsline People AIDS Coalit N Y; 1998 Mar; ():15. PubMed ID: 11367449
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Lori F; Lisziewicz J
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
[TBL] [Abstract][Full Text] [Related]
11. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Zala C; Rouleau D; Montaner JS
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S143-50. PubMed ID: 10860899
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 therapeutic vaccines.
Kinloch-de Loes S; Autran B
J Infect; 2002 Apr; 44(3):152-9. PubMed ID: 12099741
[TBL] [Abstract][Full Text] [Related]
13. Some recent results on HIV pathogenesis with implications for therapy and vaccines.
Gallo RC; Garzino-Demo A
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1101-4. PubMed ID: 11838957
[TBL] [Abstract][Full Text] [Related]
14. Tat toxoid: its potential role as an HIV vaccine.
Lambert J
J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
[No Abstract] [Full Text] [Related]
15. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
17. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
Gallo RC; Burny A; Zagury D
DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
[TBL] [Abstract][Full Text] [Related]
19. Remune trial ended.
Res Initiat Treat Action; 1999 Jul; 5(3):28. PubMed ID: 11366725
[TBL] [Abstract][Full Text] [Related]
20. New finding on immune response to HIV Tat may contribute to vaccine, treatment.
James JS
AIDS Treat News; 2000 Sep; (351):4. PubMed ID: 12173551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
